Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

The Savage City Council adopted a proclamation at its Oct. 17 meeting declaring the month of November “Pancreatic Cancer Awareness Month ... and passed out purple ribbons to the council ...

Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness, improved diagnosis and treatment.